Diagnostic Innovations in Pediatric Tuberculosis in Bolivia

Medical professionals and children observing TB imaging on a tablet in a clinic.

At a Glance

Research Area
Infectious Diseases | Pediatric Health | Diagnostic Innovation


Location
Bolivia


Funding
National Institute of Allergy and Infectious Diseases (NIAID), NIH


Tulane Faculty
Richard Oberhelman, MD | Tropical Medicine & Infectious Diseases (PI)
Bo Ning, PhD | Tulane School of Medicine (MPI)
Jeffrey G. Shaffer, PhD | Biostatistics & Data Science (CoI)


Status
Active 2023–2028 (anticipated)


Project Highlights

  • Novel CRISPR-based diagnostic technology for pediatric tuberculosis
  • Evaluation of lung ultrasound as a low-cost alternative to chest X-ray
  • International collaboration spanning more than 25 years in Peru and Bolivia
  • Potential to improve TB diagnosis in low-resource settings worldwide
Graphic: Bolivia map in blue, with its location highlighted on a world map.

Project Details

Overview

Unlike adults, children often cannot produce the respiratory samples needed for standard diagnostic tests, while advanced laboratory methods commonly used in high-income countries remain inaccessible in many parts of the world. This project is evaluating innovative approaches, specifically a novel CRISPR-based blood test and lung ultrasound, to improve the early detection of pediatric TB in Bolivia.

 

Why This Matters

Tuberculosis remains one of the world's leading infectious disease killers, yet diagnosing children with TB is especially difficult. Delayed or missed diagnoses can lead to prolonged illness, ongoing transmission, and preventable deaths. Developing affordable, accurate diagnostic tools that can be used in resource-limited settings has the potential to improve care for children in Bolivia and other high-burden countries.

 

Our Approach

Tulane and its international partners are evaluating new diagnostic technologies by:

  • Testing a novel CRISPR-mediated blood assay that detects tuberculosis DNA circulating in the bloodstream.
  • Measuring how well the new blood test distinguishes confirmed, probable, and unlikely TB cases in children.
  • Evaluating lung ultrasound as a portable, low-cost alternative to chest X-ray for identifying TB-related lung disease.
  • Combining laboratory biomarkers with imaging approaches to improve diagnostic accuracy.
  • Following children receiving TB treatment to better understand how diagnostic markers change over time.

 

Potential Impact

If successful, this research could transform how pediatric tuberculosis is diagnosed in low-resource settings by providing accurate, affordable alternatives to current diagnostic methods. The project represents an important step toward making earlier diagnosis, and ultimately earlier treatment, accessible for children living in areas where TB remains a major public health threat.

 

Featured Innovation

A novel CRISPR-mediated assay developed at Tulane University detects Mycobacterium tuberculosis cell-free DNA in blood, offering a promising approach for diagnosing pediatric tuberculosis where conventional tests are often inadequate. Learn more about Tulane's CRISPR-based TB blood test.

 

Research Partnerships

United States

  • Tulane WSPH Department of Tropical Medicine & Infectious Diseases
  • Tulane WSPH Department of Biostatistics & Data Science
  • Tulane School of Medicine
  • Johns Hopkins Bloomberg School of Public Health

Bolivia

  • Dr. Mario Ortiz Suarez Children's Hospital, Santa Cruz

Fieldnotes & Frontlines
 

Listen or watch interviews with WSPH researchers working around the world

Tulane Global Health Substack

Meet Our Faculty
 

Learn about the investigators leading this work

Faculty Directory

EXPLORE GLOBAL RESEARCH
 

Browse additional featured projects

Research 

STUDENT OPPORTUNITIES
 

Discover Practica, fellowships, and global research experiences.

Training & Opportunities